Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0028177
DC FieldValue
dc.titleEffective antibiotics in combination against extreme drug-resistant pseudomonas aeruginosa with decreased susceptibility to polymyxin B
dc.contributor.authorLim T.-P.
dc.contributor.authorLee W.
dc.contributor.authorTan T.-Y.
dc.contributor.authorSasikala S.
dc.contributor.authorTeo J.
dc.contributor.authorHsu L.-Y.
dc.contributor.authorTan T.-T.
dc.contributor.authorSyahidah N.
dc.contributor.authorKwa A.L.
dc.date.accessioned2019-11-11T08:36:06Z
dc.date.available2019-11-11T08:36:06Z
dc.date.issued2011
dc.identifier.citationLim T.-P., Lee W., Tan T.-Y., Sasikala S., Teo J., Hsu L.-Y., Tan T.-T., Syahidah N., Kwa A.L. (2011). Effective antibiotics in combination against extreme drug-resistant pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS ONE 6 (12) : e28177. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0028177
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/162021
dc.description.abstractObjective: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. Methods: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10 5 CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a ?3 log 10 CFU/ml decrease in the colony count from the initial inoculum at 24 hours. Results: 22 clinical XDR-PA isolates with PB MIC 2-16 ?g/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. Conclusion: Bactericidal activity with sustained killing effect of ?99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant. © 2011 Lim et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectamikacin
dc.subjectlevofloxacin
dc.subjectmeropenem
dc.subjectmetallo beta lactamase
dc.subjectpolymyxin B
dc.subjectrifampicin
dc.subjectamikacin
dc.subjectantiinfective agent
dc.subjectbeta lactamase
dc.subjectmeropenem
dc.subjectofloxacin
dc.subjectpolymyxin B
dc.subjectrifampicin
dc.subjectthienamycin derivative
dc.subjectantibiotic sensitivity
dc.subjectarticle
dc.subjectbacterial count
dc.subjectbacterial strain
dc.subjectbactericidal activity
dc.subjectbacterium isolate
dc.subjectcolony forming unit
dc.subjectgenotype
dc.subjectimmunocompromised patient
dc.subjectin vitro study
dc.subjectminimum inhibitory concentration
dc.subjectnonhuman
dc.subjectphenotype
dc.subjectphylogeny
dc.subjectpolymerase chain reaction
dc.subjectPseudomonas aeruginosa
dc.subjectPseudomonas infection
dc.subjectpublic hospital
dc.subjectSingapore
dc.subjectantibiotic resistance
dc.subjectdrug combination
dc.subjectdrug potentiation
dc.subjecthuman
dc.subjectmetabolism
dc.subjectmethodology
dc.subjectmicrobiological examination
dc.subjectPseudomonas infection
dc.subjecttime
dc.subjectAmikacin
dc.subjectAnti-Bacterial Agents
dc.subjectbeta-Lactamases
dc.subjectDrug Resistance, Bacterial
dc.subjectDrug Synergism
dc.subjectDrug Therapy, Combination
dc.subjectHumans
dc.subjectMicrobial Sensitivity Tests
dc.subjectOfloxacin
dc.subjectPhylogeny
dc.subjectPolymyxin B
dc.subjectPseudomonas aeruginosa
dc.subjectPseudomonas Infections
dc.subjectRifampin
dc.subjectThienamycins
dc.subjectTime Factors
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.description.doi10.1371/journal.pone.0028177
dc.description.sourcetitlePLoS ONE
dc.description.volume6
dc.description.issue12
dc.description.pagee28177
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0028177.pdf172.53 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons